Teva Pharmaceutical Industries Limited (TEVA) Given “Neutral” Rating at Piper Jaffray Companies

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “neutral” rating reaffirmed by analysts at Piper Jaffray Companies in a note issued to investors on Friday. They currently have a $23.00 target price on the stock, down from their previous target price of $28.00. Piper Jaffray Companies’ price objective would indicate a potential upside of 25.75% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. Vetr cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a research note on Thursday, June 22nd. BTIG Research reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, April 6th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Finally, Maxim Group reiterated a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, twenty have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $39.19.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 18.29 on Friday. The stock has a market cap of $18.58 billion, a P/E ratio of 234.49 and a beta of 0.46. The firm’s 50-day moving average is $32.05 and its 200-day moving average is $32.28. Teva Pharmaceutical Industries Limited has a 12 month low of $18.21 and a 12 month high of $55.45.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.25 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.44 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-earns-hold-rating-from-piper-jaffray-companies/1404255.html.

Large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 21.1% in the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock valued at $4,125,000 after buying an additional 21,658 shares in the last quarter. Shelter Mutual Insurance Co purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $133,000. Cambridge Investment Research Advisors Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 17.5% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 36,206 shares of the company’s stock valued at $1,203,000 after buying an additional 5,381 shares in the last quarter. NTV Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $247,000. Finally, Buckingham Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $592,000. Institutional investors and hedge funds own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.